All-Island · NI Cross-Border
← Back to orb
Cross-border medical cannabis flow

Belfast is taking ROI patients today. That's both a threat and a lever.

Republic of Ireland patients with non-MCAP indications - chronic pain, anxiety, sleep disorders - currently route through the Curaleaf clinic in Belfast for private-pay UK prescriptions. The cross-border mechanism is well-trodden. Today, none of those patients are Oleo's. The April 2026 MCAP review may bring them home.

How the cross-border path works.

  1. ROI patient with a non-MCAP indication (chronic pain, anxiety, sleep) travels to Belfast.
  2. Sees a Curaleaf prescriber. Private-pay model, no NHS or HSE coverage.
  3. Prescription issued under UK regulatory regime (MHRA, Specials).
  4. Patient returns to ROI with prescription. Fulfilment via cross-border pharmacy or Dutch ministerial-licence channel.
  5. Outside MCAP scope. No HSE reimbursement. Out-of-pocket cost.

Legal mechanism: S.I. 540/2003 + EU cross-border healthcare directive.

The strategic position.

Threat (today)

Belfast captures the ROI patient who has anything other than MS spasticity, chemo nausea, or refractory epilepsy. UK private-pay model is faster than MCAP today (Belfast same-week, MCAP can take months).

The patients who route via Curaleaf are price-tolerant, motivated, and already cannabis-curious. They are exactly the patient profile Oleo would serve if MCAP eligibility expanded.

Lever (post-review)

If MCAP eligibility widens after the April 2026 review, those patients become eligible for Oleo. Being the visible, named, ROI-resident supplier matters when they look for a domestic option.

A single page on /mcap/cross-border-options that explains this honestly is a high-trust acquisition asset. Most patients researching options have nothing else this clear to find.

Action item for the orb: the cross-border-options explainer page is part of the Track 2 content roadmap (see growth plan). It is unbranded, regulator-aligned, patient-helpful. Captures the right demographic without breaching ASAI rules.
The supply-side counterpart

Bedrocan-grade product, properly framed.

Cross-border patient flow is the demand side. The supply side is Bedrocan. Oleo distributes Bedrocan-grade product into Ireland under MCAP - the same standard cannabis flower that the Netherlands' Office of Medicinal Cannabis distributes nationally. That supply-chain authority is a real trust signal that the current oleo.ie does not surface.

What we will say

  • Oleo distributes Bedrocan-grade product into Ireland under MCAP
  • Same standard the Netherlands' Office of Medicinal Cannabis distributes nationally
  • Sources verified through HPRA-authorised import licences
  • Batch-level traceability per HPRA controlled-drug requirements
  • One dedicated supply-chain page describing the chain at the level pharmacists need

What we will not say

  • No co-marketing claims
  • No partnership branding (joint logos, etc.)
  • No implied exclusivity
  • No language suggesting Oleo speaks for Bedrocan
  • Every public mention reviewable by Richard before publishing

Hard rule: every Bedrocan reference verified with Richard before publishing. Conservative posture by default. If Bedrocan ever objects, the reference is pulled within 24 hours.

← Back to orb